$48.54
0.58% today
Nasdaq, Nov 26, 04:51 pm CET
ISIN
US47103J1051
Symbol
JANX
Sector
Industry

Janux Therapeutics Inc Target price 2024 - Analyst rating & recommendation

Janux Therapeutics Inc Classifications & Recommendation:

Buy
92%
Hold
8%

Janux Therapeutics Inc Price Target

Target Price $67.27
Price $48.82
Potential
Number of Estimates 11
11 Analysts have issued a price target Janux Therapeutics Inc 2025 . The average Janux Therapeutics Inc target price is $67.27. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 13 analysts: 12 Analysts recommend Janux Therapeutics Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Janux Therapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the Janux Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 8.08 12.59
6.16% 55.81%
EBITDA Margin -878.96% -667.55%
14.23% 24.05%
Net Margin -855.06% -514.78%
7.46% 39.80%

12 Analysts have issued a sales forecast Janux Therapeutics Inc 2024 . The average Janux Therapeutics Inc sales estimate is

$12.6m
Unlock
. This is
3.53% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$27.9m 114.12%
Unlock
, the lowest is
$10.6m 18.87%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $8.1m 6.16%
2024
$12.6m 55.81%
Unlock
2025
$5.9m 53.28%
Unlock
2026
$13.0m 121.73%
Unlock
2027
$9.8m 25.23%
Unlock
2028
$95.8m 882.05%
Unlock

2 Analysts have issued an Janux Therapeutics Inc EBITDA forecast 2024. The average Janux Therapeutics Inc EBITDA estimate is

$-84.0m
Unlock
. This is
0.19% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-65.5m 21.88%
Unlock
, the lowest is
$-103m 22.27%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-71.0m 7.20%
2024
$-84.0m 18.34%
Unlock
2025
$-116m 37.79%
Unlock
2026
$-147m 26.71%
Unlock

EBITDA Margin

2023 -878.96% 14.23%
2024
-667.55% 24.05%
Unlock
2025
-1,968.65% 194.91%
Unlock
2026
-1,124.95% 42.86%
Unlock

8 Janux Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Janux Therapeutics Inc net profit estimate is

$-64.8m
Unlock
. This is
4.94% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-39.0m 36.79%
Unlock
, the lowest is
$-73.8m 19.49%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-69.1m 13.16%
2024
$-64.8m 6.19%
Unlock
2025
$-94.6m 46.03%
Unlock
2026
$-154m 63.21%
Unlock
2027
$-181m 17.33%
Unlock
2028
$-120m 33.58%
Unlock

Net Margin

2023 -855.06% 7.46%
2024
-514.78% 39.80%
Unlock
2025
-1,608.84% 212.53%
Unlock
2026
-1,184.25% 26.39%
Unlock
2027
-1,858.22% 56.91%
Unlock
2028
-125.69% 93.24%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -1.32 -1.24
13.16% 6.06%
P/E negative
EV/Sales 153.11

8 Analysts have issued a Janux Therapeutics Inc forecast for earnings per share. The average Janux Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.24
Unlock
. This is
5.08% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.75 36.44%
Unlock
, the lowest is
$-1.41 19.49%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.32 13.16%
2024
$-1.24 6.06%
Unlock
2025
$-1.81 45.97%
Unlock
2026
$-2.95 62.98%
Unlock
2027
$-3.46 17.29%
Unlock
2028
$-2.30 33.53%
Unlock

P/E ratio

Current -41.52 564.32%
2024
-39.43 5.03%
Unlock
2025
-27.00 31.52%
Unlock
2026
-16.54 38.74%
Unlock
2027
-14.10 14.75%
Unlock
2028
-21.23 50.57%
Unlock

Based on analysts' sales estimates for 2024, the Janux Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

153.11
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
203.52
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 147.71 1,135.03%
2024
153.11 3.65%
Unlock
2025
327.69 114.02%
Unlock
2026
147.78 54.90%
Unlock
2027
197.64 33.74%
Unlock
2028
20.13 89.82%
Unlock

P/S ratio

Current 196.33 290.25%
2024
203.52 3.66%
Unlock
2025
435.57 114.02%
Unlock
2026
196.44 54.90%
Unlock
2027
262.71 33.74%
Unlock
2028
26.75 89.82%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today